Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Patients with Psoriasis from the PsoBioTeq Cohort

Abstract

Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of additional biological (bDMARDs) or synthetic (sDMARDs) systemic treatments. We aimed to determine whether the increasing number of available systemic treatment in psoriasis over time affects drug survival. We used the Psobioteq cohort, a French prospective observational cohort enrolling patients with moderate to severe psoriasis. All patients initiating a first bDMARD or sDMARD were included. The primary outcome was the comparison of the drug survival over time. A multivariate cox proportional hazard ratio model was computed. There were 1,866 patients included, 739 females (39%) with a median age of 47 years. In multivariate Cox model, no association was found between the calendar year of initiation and drug survival (HR overlapping from 0.80 (0.42-1.52) to 1.17 (0.64-2.17), p=0.633). In conclusion, drug survival in psoriasis is not affected by the year of initiation.

Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real‐life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists

“…In two children from two centers, the combined therapy involved three associated treatments: acitretin–methotrexate and a TNF‐alpha inhibitor. The frequency of use of combined therapies reported in our study is higher than that reported for adults in the PsoNet network of international registries (9.9%) and in the French PsoBioteq cohort (12%) 26,27 . Among the 48 combined therapies, we identified 14 different combinations involving acitretin, methotrexate, or cyclosporin with one of five biologics from three different classes, that is, TNF‐alpha inhibitors, interleukin‐12/23 inhibitors and interleukin‐17 inhibitors.…”

“…The frequency of use of combined therapies reported in our study is higher than that reported for adults in the PsoNet network of international registries (9.9%) and in the French PsoBioteq cohort (12%). 26,27 Among the 48 combined therapies, we identified 14 different combinations involving acitretin, methotrexate, or cyclosporin with one of five biologics from three different classes, that is, TNF-alpha inhibitors, interleukin-12/23 inhibitors and interleukin-17 inhibitors. TNF-alpha inhibitors associated with acitretin or methotrexate were the most frequently used combined therapies.…”

Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database

“…These sensitivity analyses and the main analysis yielded similar results, which support our main findings. Last, a previous study of 1866 patients showed that the drug persistence in PsO was not affected by the year of treatment initiation. Finally, the database analyzed in this study did not specify the reasons why a patient stopped filling prescriptions for a biologic, which could include loss of efficacy, occurrence of an adverse effect, presence of comorbidities, or extrinsic factors such as a wider range of treatment options or a lower price for biosimilar products .…”

Impact of the first wave of the COVID-19 pandemic on the treatment of psoriasis with systemic therapies in France: Results from the PSOBIOTEQ cohort

“…Furthermore, in many healthcare systems the pandemic led to difficulties in managing patients with chronic diseases because of the suspension of most outpatient services and the redeployment of physicians from other medical specialties to the care of COVID-19 patients [14] . The objectives of this study were to describe systemic treatment modifications during the first wave of the COVID-19 pandemic in France among psoriasis patients included in the French PSOBIOTEQ cohort [15] , [16] , [17] , [18] , [19] , and to estimate the incidence of COVID-19 among these patients during this period. In addition, the factors associated with these events were evaluated.…”